A Study to Evaluate Solriktug in Adult Participants With Asthma
NCT06496607 · Asthma
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereMobile, Alabama, United States + 73 more
SponsorUniquity One (UNI)
▾Tap for detailsClick for full details — eligibility, all locations, contacts
74 sitesApply